Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tibolone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Mithra Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets
Details : BioSyent has acquired intellectual property, global rights, certain licensing, distribution and supply agreements related to Tibelia (tibolone), a prescription hormone replacement therapy.
Product Name : Tibelia
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 20, 2024
Lead Product(s) : Tibolone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Mithra Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Recipient : Undisclosed
Deal Size : Undisclosed
Deal Type : Licensing Agreement
BioSyent In-Licenses Endocrinology Product for Canada
Details : Under the licensing agreement, BioSyent aims to market, sell & distribute a new endocrinology product in Canada. BioSyent and its European partner will seek Health Canada approval by the end of 2024.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Recipient : Undisclosed
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Licensing Agreement
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
Details : Under the agreement, BioSyent extended its agreement with its European partner for RepaGyn (sodium hyaluronate) and Proktis-M, extending its exclusive Canadian rights to these products until 2032.
Product Name : Repagyn
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 15, 2024
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Inositol,Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Details : Inofolic is a natural health product, combining myo-inositol and folic acid in a unique soft-gel capsule for women living with PCOS. Inofolic® helped 70% of women with PCOSii to regulate their menstrual cycles throughout the 16-week study period.
Product Name : Inofolic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Inositol,Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polydextrose Iron Complex
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioSyent Announces Launch of New FeraMAX Pd Maintenance 45
Details : FeraMAX (polydextrose iron complex) Maintenance 45 is designed to prevent iron deficiency, maintain healthy iron levels and to address a gap of iron health in women’s health and the management of iron health across various life stages.
Product Name : FeraMAX
Product Type : Carbohydrate
Upfront Cash : Inapplicable
March 07, 2023
Lead Product(s) : Polydextrose Iron Complex
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
